Veterinary Medicines

Versican Plus DHP lyophilisate and solvent for suspension for injection for dogs

Authorised
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
  • Canine distemper virus, strain CDV Bio 11/A, Live
Download as PDF

Product identification

Medicine name:
Versican Plus DHP lyophilisate and solvent for suspension for injection for dogs
Versican Plus DHP Frystorkat pulver och vätska till injektionsvätska, suspension
Active substance:
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
  • Canine distemper virus, strain CDV Bio 11/A, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
    19953.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
    3981.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain CDV Bio 11/A, Live
    1259.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Sweden
Package description:
  • (ID2): 1 Box with (50 Vial (Glass) with 1 Dose and 50 Vial (Glass) with 1 ml) (50.0 Dose, 50.0 ml)
  • (ID1): 1 Box with (25 Vial (Glass) with 1 Dose and 25 Vial (Glass) with 1 ml) (25.0 Dose, 25.0 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Animal Health ApS
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Swedish Medical Products Agency
Authorisation number:
  • 52903
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0267/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Cyprus
  • Denmark
  • Finland
  • Greece
  • Hungary
  • Italy
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 14/02/2022
Download
Swedish (PDF)
Published on: 12/06/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 12/06/2023
Download

Combined File of all Documents

English (PDF)
Published on: 24/05/2023
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 12/06/2023
Download

2613563-paren-20251101.pdf

English (PDF)
Published on: 8/12/2025
Download